when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

425 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT799 Endpoints604 BioPharma Dive231 onclive165 Fierce Biotech74 BioSpace69 raps29

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6

<![CDATA[Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL]]>
<![CDATA[Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.]]>
onclive · 2mo ago↗ source
<![CDATA[The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer]]>
<![CDATA[Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreat…
onclive · 2mo ago↗ source
<![CDATA[Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study ]]>

page 14 of 17

Infectious Disease4

<![CDATA[This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea…

onclive · 2mo ago↗ source

<![CDATA[First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC]]>

<![CDATA[Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.]]>

onclive · 2mo ago↗ source

<![CDATA[Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability]]>

<![CDATA[This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and st…

onclive · 2mo ago↗ source

Odyssey, on second try, snags $279M in an IPO

<figure><div><img src="https://imgproxy.divecdn.com/szYDL8kkQd6XaSVgvjJPYl2j0snveijWs_0sZ-B522Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDYyODUzODA3LmpwZ…

BioPharma Dive · 2mo ago↗ source

<![CDATA[Dr Sznol on Optimal Treatment Sequencing in Melanoma]]>

<![CDATA[Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data. ]]>

onclive · 2mo ago↗ source

<![CDATA[Mentorship Is Key to Advance the Next Generation of Oncology Researchers]]>

<![CDATA[Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators. ]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Mauro on the Significance of Alternative TKI Formulations in CML]]>

<![CDATA[Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.]]>

onclive · 2mo ago↗ source

Sarepta tumbles as its gene therapy sales decline further

<figure><div><img src="https://imgproxy.divecdn.com/XaTqfcte0RAZt6-RIcgWQ5i2KmL-mKKasPXR8xjfQW8/g:nowe:0:858/c:4256:2405/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TYXJlcHRhX0Jvc…

BioPharma Dive · 2mo ago↗ source

<![CDATA[Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn]]>

<![CDATA[Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC]]>

<![CDATA[Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.]]>

onclive · 2mo ago↗ source

<![CDATA[Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer]]>

<![CDATA[Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.]]>

onclive · 2mo ago↗ source

<![CDATA[Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.]]>

<![CDATA[Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.]]>

onclive · 2mo ago↗ source

<![CDATA[FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease]]>

<![CDATA[The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.]]>

onclive · 2mo ago↗ source

<![CDATA[ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies]]>

<![CDATA[Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>

onclive · 2mo ago↗ source

Angelini to buy Catalyst in $4B play for rare neuro drugs

<figure><div><img src="https://imgproxy.divecdn.com/4_eQ3BQP0sHe3AjR5s7bySznoaDhyqMpmhkmNubOdkU/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDQwMTY4MDMyXzEua…

BioPharma Dive · 2mo ago↗ source

Entrada shares dive as Duchenne results disappoint

<figure><div><img src="https://imgproxy.divecdn.com/xa_T0oT9Hj8F-wJjKfJeFkbn4Yqp_lT58dL0S4GszxY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy02MjEzNjQ4MDJfMS5qc…

BioPharma Dive · 2mo ago↗ source

Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B

<figure><div><img src="https://imgproxy.divecdn.com/Q9vt9_gxDkyyl1zgpo6ZBBNf6InJ95ZMxSRGRm4nTFk/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8yQTROWEtOLmpwZw==.webp"/></div></f…

BioPharma Dive · 2mo ago↗ source

<![CDATA[Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026]]>

<![CDATA[Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.]]>

onclive · 2mo ago↗ source

<![CDATA[EGFR-Targeted Therapy Sequencing After Resistance in NSCLC]]>

<![CDATA[Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.]]>

onclive · 2mo ago↗ source

<![CDATA[HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations]]>

<![CDATA[Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.]]>

onclive · 2mo ago↗ source

<![CDATA[Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>

<![CDATA[Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.]]>

onclive · 2mo ago↗ source

<![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>

<![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>

onclive · 2mo ago↗ source

<![CDATA[Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response]]>

<![CDATA[Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.]]>

onclive · 2mo ago↗ source